MyoKardia, Inc. is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction.
News & Events
May 9, 2017
MyoKardia Reports First Quarter 2017 Financial Results and Operational Progress
April 18, 2017
MyoKardia Appoints David Meeker, M.D., to Board of Directors
March 17, 2017
MyoKardia Appoints Kim Popovits and Wendy Yarno to Board of Directors
March 13, 2017
MyoKardia Reports Fourth Quarter and Full Year 2016 Financial Results and Operational Progress
February 2, 2017
First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491